Go back to trials list
A Phase 1 Dose Escalation/Dose Finding Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Description
Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Trial Eligibility
Inclusion Criteria: * Histologically or cytologically documented locally advanced or metastatic solid tumor malignancy. * Adequate bone marrow, kidney and liver function * Performance status of 0 or 1. * Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade 1 except for AEs not constituting a safety risk by Investigator judgement. Exclusion Criteria: * Prior treatment targeting ILT3. * Prior treatment targeting LAIR1.
Study Info
Organization
NGM Biopharmaceuticals, Inc
Primary Outcome
Number of Patients with Dose-limiting Toxicities
Interventions
Locations Recruiting
NGM Clinical Study Site
United States, Arizona, Gilbert
NGM Clinical Study Site
United States, California, Los Angeles
NGM Clinical Study Site
United States, Florida, Sarasota
NGM Clinical Study Site
United States, Florida, Tampa
NGM Clinical Study Site
United States, Michigan, Grand Rapids
Interested in joining this trial?
Our dedicated patient navigators are here to guide you through the validation and enrollment process with ease.
Get the latest thought leadership on your Peripheral T-Cell Lymphoma delivered straight to your inbox
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.